about
Novel stabilin-1 interacting chitinase-like protein (SI-CLP) is up-regulated in alternatively activated macrophages and secreted via lysosomal pathwayThe Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer ProgressionImmortalization eliminates a roadblock during cellular reprogramming into iPS cellsChromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastasesPhase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanomaHyperthermia Influences the Effects of Sodium Channel Blocking Drugs in Human-Induced Pluripotent Stem Cell-Derived CardiomyocytesInduced pluripotent stem cells generated without viral integrationDirectly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contributionImproved survival with MEK inhibition in BRAF-mutated melanomaCoexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer.Molecular genetics of Xeroderma pigmentosum variant.[Allergic contact dermatitis from colophony and turpentine in resins of untreated pine wood]Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.Desmoglein 2 depletion leads to increased migration and upregulation of the chemoattractant secretoneurin in melanoma cells.Predominant telangiectatic erythema in linear atrophoderma of Moulin: novel variant or separate entity?Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma.SOX5 is involved in balanced MITF regulation in human melanoma cells.Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia: case report.Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma.Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.Dose-dependent roles for canonical Wnt signalling in de novo crypt formation and cell cycle properties of the colonic epithelium.mRNA-based dendritic cell immunization improves survival in ret transgenic mouse melanoma model.Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapy.From skin to the treatment of diseases--the possibilities of iPS cell research in dermatology.Mediators of induced pluripotency and their role in cancer cells - current scientific knowledge and future perspectives.Systemic therapy of non-resectable metastatic melanoma.De- and re-differentiation of the melanocytic lineage.Extracellular adenosine metabolism in immune cells in melanoma.Novel insights into exosome-induced, tumor-associated inflammation and immunomodulation.From skin to other cell types of the body.Myeloid-derived suppressor cells in malignant melanoma.New therapeutic options for advanced non-resectable malignant melanoma.Function and significance of MicroRNAs in benign and malignant human stem cells.MicroRNAs as novel targets and tools in cancer therapy.Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.Multiple roles of NF1 in the melanocyte lineage.Impact of preconditioning with retinoic acid during early development on morphological and functional characteristics of human induced pluripotent stem cell-derived neurons.Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients.Myeloid-derived suppressor cells and tumor escape from immune surveillance.
P50
Q24298961-E8921BAA-CD7C-4BC7-B043-DA367F46B29CQ28076760-7D649929-3685-4C7B-B415-7A89B3BE3C33Q28254388-2AA1452A-1D5E-4A89-B7F3-4354BC80952AQ28345662-C21B77E7-93A0-4C6F-AAA4-DA556AA82629Q28543960-5B82E712-E71A-4AC6-ABFC-6AC670C604C9Q28553287-D9CA8192-97F6-45A6-8651-8DA9005D3157Q29614343-2E934EBD-DAC2-4FB0-888C-95ACB803D428Q29616187-7288DFE3-E038-4F8B-8F60-544F850E841FQ29620663-679E2003-4C8D-4A69-B240-16A4AC2C35B1Q31882118-CECE8AA4-9EF9-47C0-AB2A-4168C96A0656Q33196452-68A9E9FE-FB2C-44D9-9155-D1FE6032E82BQ34500313-84A7482A-2CA4-4618-AA5F-FE254F7B892AQ34664981-1399627A-65F7-4098-ADA8-5AC3EFF5E113Q35099880-EE5DC5AE-81FB-4AD1-A854-8DAFCF67144AQ35565022-90F3D4CF-25AC-4A1C-AB4F-3A621410CE4DQ35611909-72185B9B-87F6-4F38-BAD8-236123B1E2FAQ35939947-9A3ADDAB-348D-494D-816B-209DAF476792Q36153854-AE1816F8-B1AC-48E6-9BF3-57D8BBE3806DQ36256712-0E3181AF-3ABC-42E1-BC06-932B07572712Q36397395-64027A25-76EC-4DBB-AB8E-B19958F8781BQ36413900-D802C4AF-9612-4EB1-BADA-F54162D93D71Q36444132-AF8ECD3E-4B24-4B38-B1B8-5883C42C13F9Q37079145-C1383C90-6008-48FD-80BC-FA3ADB84C269Q37433032-BED53D39-BF0F-47AD-A915-F16F6370378BQ37876469-39530CED-7CA6-42B6-985C-386A5B51843EQ38010413-E8104CEC-8F6D-431C-9E2A-715AF1B48EDAQ38166572-1006861F-58D0-40A2-B761-D323EED2C08FQ38173449-89A2BF0E-C2CC-4527-8C9F-9DEB7B73D89EQ38206399-A3FEB31B-F458-4493-9C9B-CD7A47298CEEQ38207414-60F90485-0972-47E5-9C37-553F1B667525Q38236462-3EC0ED15-BE4A-46D8-ABFF-930C3F7E291BQ38254999-7DDE6C49-7819-4A37-9BA3-8E1B081FF26BQ38321800-58E81A3E-6655-4872-A71E-A75503AD723FQ38550782-0129277A-F3F9-4C9C-8109-813078692D01Q38798381-6DFABD53-5223-440F-AF1F-9EB625FA8710Q38802138-2D9B3B9C-11F7-4C4A-BA42-FF6D391DD7F3Q38828126-C43452DA-8AF9-40D5-8BAE-88D318EFA8ABQ38871991-5B10ACB5-B102-410E-B8AA-335FE4BBF40AQ38944200-9A6246AF-33CE-4FF6-942A-A4C9BBF0D3CBQ38992562-2A4D2F6A-318D-4C13-B996-D8A304B5F42F
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Jochen Utikal
@ast
Jochen Utikal
@en
Jochen Utikal
@es
Jochen Utikal
@nl
Jochen Utikal
@sl
type
label
Jochen Utikal
@ast
Jochen Utikal
@en
Jochen Utikal
@es
Jochen Utikal
@nl
Jochen Utikal
@sl
prefLabel
Jochen Utikal
@ast
Jochen Utikal
@en
Jochen Utikal
@es
Jochen Utikal
@nl
Jochen Utikal
@sl
P214
P227
P101
P106
P1153
6601969918
P21
P213
0000 0003 8307 4103
P214
P227
1026463750
P31
P496
0000-0001-5316-0241
P569
1974-01-01T00:00:00Z
P735
P7859
viaf-268302420